Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 5, 2001, Pages 405-412

  Nelson, Patrick W ^a   Mittler, John E ^b   Perelson, Alan S ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

HIV HIV pathogenesis; Mathematical modeling; Viral dynamics

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DEATH; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION;

EID: 0035870707     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200104150-00002     Document Type: Article

References (38)

1. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-91.
2. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70: 7894-9.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
4. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373: 117-22.
5. Nowak MA, Lloyd A, Vasquez G. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997;71:7518-25.
6. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996;271:1582-6.
7. Herz VM, Bonhoeffer S, Anderson RM, May RM, Nowak MA. Viral dynamics in vivo: limitations on estimations on intracellular delay and virus decay. Proc Natl Acad Sci USA 1996;93:7247-51.
8. Hlavacek WS, Wofsy C, Perelson AS. Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proc Natl Acad Sci USA 1999;96:14681-6.
9. Hlavacek WS, Stilianakis NI, Notermans DW, Danner SA, Perelson AS. Influence of follicular dendritic cells on decay of HIV-1 type 1 during antiretroviral therapy. Proc Natl Acad Sci USA 2000; 97:10966-71.
10. Finzi D, Siliciano RF. Viral dynamics in HIV-1 infection. Cell 1998;93:665-71.
11. Notermans D, Goudsmit J, de Wolf F, Danner S, Perelson A, Mittler J. Rate of decline of HIV-1 following antiretroviral therapy is related to viral load at baseline and drug regimen. J Acquir Immune Defic Syndr 1998;12:1483-90.
12. Grossman Z, Feinberg M, Kuznetsov V, Dimitrov D, Paul W. HIV infection: how effective is drug combination treatment. Immunol Today 1998;19:528-32.
13. Ho D, Ramratnam M, Louie M, et al. Latent reservoir and residual HIV-1 replication on antiretroviral therapy. Presented at the Eighth Conference on Retrovirology and Opportunistic Infections, Chicago, February 4-8, 2001.
14. Furtado MR, Callaway DS, Phair JP, Macken CA, Perelson AS, Wolinsky SM. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-22.
15. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-13.
16. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med 2000;6:76-81.
17. Ferguson N, deWolf F, Ghani A, et al. Antigen-driven CD4+T cell and HIV-1 dynamics: residual viral replication under highly active antiviral therapy. Proc Natl Acad Sci USA 1999;96:15167-72.
18. Grossman Z, Polis M, Feinberg MB, et al. Ongoing HIV dissemination during HAART. Nat Med 1999;5:1099-104.
19. Louie M, Ramratnam B, Kost R, et al. Using viral dynamics to document the greater antiviral potency of a regimen containing Lopinavir/Ritonavir, Efavirenz, Tenofovir, and Lamivudine related to standard HAART. Presented at the Eighth Conference on Retrovirology and Opportunistic Infections. Chicago, February, 4-8, 2001.
20. Wein LM, D'Amato RM, Perelson AS. Mathematical considerations of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theoret Biol 1998;192:81-98.
21. Perelson AS, Nelson PW. Mathematical models of HIV dynamics in vivo. SIAM Review 1999;41:3-44.
22. Ding AA, Wu H. Relationship between antiviral treatment effects and biphasic decay rates in modeling HIV dynamics. Math Biosci 1999;160:63-82.
23. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci USA 1997;94:6971-6.
24. Nelson PW, Murray JD, Perelson AS. A model of HIV-1 pathogenesis that includes an intracellular delay. Math Biosci 2000;163: 201-15.
25. Mittler JE, Sulzer B, Neumann AU, Perelson AS. Influence of delayed virus production on viral dynamics in HIV-1 infected patients. Math Biosci 1998;152:143-63.
26. Guatelli JC, Gingeras TR, Richman DD. Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells. J Virol 1990;64:4093-8.
27. Pellegrino MG, Li G, Potash MJ, Volsky DJ. Contribution of multiple rounds of viral entry and reverse transcription to expression of human immunodeficiency virus type 1. J Biol Chem 1991;266: 1783-9.
28. Kim S, Byrn R, Groopman J, Baltimore D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 1989; 63:3708-12.
29. Mittler JE, Markowitz M, Ho DD, Perelson AS. Refined estimates for HIV-1 clearance rate and intracellular delay. J Acquir Immune Defic Syndr 1999;13:1415-7.
30. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
31. Mosier DE, Sprent J, Tough D, et al. Scientific correspondence. Nature 1995;375:194-198.
32. Ramratnam B, Bonhoeffer S, Binley J. et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancer 1999;354:1782-5.
33. Austin DJ, White NJ, Anderson RM. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol 1998;194:313-9.
34. Wahl L, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc R Soc Lond B Biol Sci 2000;267: 835-43.
35. Klenerman P, Phillips RE, Rinaldo CR, et al. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc Natl Acad Sci USA 1996;93:15323-8.
36. Wu H, Kuritzkes D, McClernon D, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologie end points. J Infect Dis 1998;179:799-807.
37. Wu H, Ding A, De Gruttola V. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations. J Acquir Immune Defic Syndr 1999;13:429-30.
38. Neumann AU, Tubiana R, Calvez V, Robert C, Autran B, Katlama C. Multi-phasic HIV decline following triple drug antiviral therapy is correlated with viral rebound dynamics during therapy interruption [abstract 517]. In Program and abstracts of the fifth conference on retroviruses and opportunistic infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.